Evidence map›Paper›PMID 30809600›Full record

ReviewNon-coding RNA research2018

Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma.

Bernhard Biersack

Erratum issuedOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Non-coding RNA research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. lncRNA ZEB2-AS1 Aggravates Progression of Non-Small Cell Lung Carcinoma via Suppressing PTEN Level.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Bernhard BiersackOrganic Chemistry Laboratory, University of Bayreuth, Universitätsstraße 30, 95447, Bayreuth, Germany.
University of Bayreuth · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemcitabine and pemetrexed are clinically approved antimetabolites for the therapy of mesothelioma diseases. These drugs are often applied in combination with platinum complexes and other drugs. The activity of antimetabolites depended on the expression levels of certain non-coding RNAs, in particular, of small microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). The development of tumor resistance towards antimetabolites was regulated by non-coding RNAs. An overview of the interplay between gemcitabine/pemetrexed antimetabolites and non-coding RNAs in mesothelioma is provided. Further to this, various non-coding RNA-modulating agents are discussed which displayed positive effects on gemcitabine or pemetrexed treatment of mesothelioma diseases. A detailed knowledge of the connections of non-coding RNAs with antimetabolites will be constructive for the design of improved therapies in future.

Indexed as

AKBA, 3-acetyl-11-keto-β-boswellic acidAnticancer drugsBcl-2, B-cell lymphoma 2DADS, diallyl sulfideDHA, docosahexaenoic acidDIM, 3,3‘-diindolylmethaneDMPM, diffuse malignant peritoneal mesotheliomaEGCG, epigallocatechin-3-gallateEMT, epithelial-mesenchymal transitionGemcitabineHOTAIR, HOX transcript antisense RNAI3C, indole-3-carbinolLong non-coding RNAMALAT1, metastasis-associated lung adenocarcinoma transcript 1MesotheliomaMicroRNAMPM, malignant pleural mesotheliomaNaB, sodium butyrateNSCLC, non-small cell lung cancerPDCD4, programmed cell death 4PEG, polyethylene glycolePEITC, phenethylisothiocyanatePemetrexedPTEN, phosphatase and tensin homologRA, retinoic acidSAHA, suberoylanilide hydroxamic acidSFN, sulforaphaneTSA, trichostatin A

Identifiers

PMID30809600
PMCPMC6257890
OpenAlexW2898840384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.